CHICAGO, June 7, 2010 (GLOBE NEWSWIRE) -- Harbor BioSciences, Inc. (Nasdaq:HRBR) today presented new positive data from its ongoing Phase I/IIa clinical trial with Apoptone® (HE3235) for castration resistant prostate cancer (CRPC) – also referred to as hormone resistant prostate cancer – at the American Society of Clinical Oncology (ASCO) Annual Meeting. The most current results from this study included data on the 100 mg cohort of chemotherapy-naive patients indicating a median time to progression of greater than 16 weeks with 80% remaining on treatment, new cohorts of patients tested at the highest dose of 350 mg, and indication of activity at all dose levels including the lowest dose of 10 mg. As no dose-limiting toxicity has been found to date, the trial continues to accrue patients, with a dose escalation group that will receive 700 mg/day.
